Abafungin
Identification
- Generic Name
- Abafungin
- DrugBank Accession Number
- DB06395
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 378.49
Monoisotopic: 378.151432518 - Chemical Formula
- C21H22N4OS
- Synonyms
- Abafungin
- Abafungina
- Abafungine
- Abafunginum
- External IDs
- BAY W 6341
- BAY-W-6341
Pharmacology
- Indication
Investigated for use/treatment in fungal infections, bacterial infection, skin infections/disorders, and onychomycosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Abafungin has been shown to have fungicidal and fungistatic effects on a wide variety of pathogens, including dermatophytes, yeasts (Candida) and moulds. The drug acts on the infecting organisms in two ways: by interfering with the formation of a vital sterol in the fungal cell membrane, thereby preventing cell growth, and also by direct interaction with another membrane component resulting in membrane disruption, leakage of cellular contents and death of the cell and independent of whether it is in a non-metabolising (`resting') phase of development or actively growing. These features of abafungin, combined with the attainment of microbicidal concentrations in the skin from a 1% preparation, its long residence at the site of dermal application and the lack of significant systemic absorption, mean that Abasol(tm) is particularly attractive for the topical treatment of dermatomycoses, which is the first indication under review for marketing approval.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Abafungin. Almasilate Almasilate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy. Amiodarone The therapeutic efficacy of Abafungin can be increased when used in combination with Amiodarone. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Abasol
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylethers
- Direct Parent
- Diphenylethers
- Alternative Parents
- Diarylethers / m-Xylenes / Phenoxy compounds / Phenol ethers / 2,4-disubstituted thiazoles / Hydropyrimidines / 2-amino-1,3-thiazoles / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds show 4 more
- Substituents
- 1,3-thiazol-2-amine / 1,4,5,6-tetrahydropyrimidine / 2,4-disubstituted 1,3-thiazole / Aromatic heteromonocyclic compound / Azacycle / Azole / Carboximidamide / Diaryl ether / Diphenylether / Ether show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- aromatic ether, guanidines, 1,3-thiazole (CHEBI:76005)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 11DI31LWXF
- CAS number
- 129639-79-8
- InChI Key
- TYBHXIFFPVFXQW-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)
- IUPAC Name
- N-{4-[2-(2,4-dimethylphenoxy)phenyl]-1,3-thiazol-2-yl}-1,3-diazinan-2-imine
- SMILES
- CC1=CC(C)=C(OC2=CC=CC=C2C2=CSC(N=C3NCCCN3)=N2)C=C1
References
- General References
- Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC: Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy. 2008;54(4):245-59. doi: 10.1159/000142334. Epub 2008 Jun 30. [Article]
- External Links
- PubChem Compound
- 159326
- PubChem Substance
- 347827768
- ChemSpider
- 140124
- ChEBI
- 76005
- ChEMBL
- CHEMBL3989547
- ZINC
- ZINC000003938976
- Wikipedia
- Abafungin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00354 mg/mL ALOGPS logP 4.55 ALOGPS logP 4.79 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 19.86 Chemaxon pKa (Strongest Basic) 6.54 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 58.54 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 110.35 m3·mol-1 Chemaxon Polarizability 41.12 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-d60ed3e056aea2eaaa9a Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0109000000-c5759d09160c29ef1a3a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0119000000-b3d1ce855d3cd38348e9 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0593000000-1c0980d203e494657015 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0pbc-6498000000-98b4200abacce9f1ccca Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0fk9-1694000000-3fc60cec5f177913f666 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 185.9102 predictedDeepCCS 1.0 (2019) [M+H]+ 188.2682 predictedDeepCCS 1.0 (2019) [M+Na]+ 195.40263 predictedDeepCCS 1.0 (2019)
Drug created at March 19, 2008 16:28 / Updated at February 21, 2021 18:52